Posted by Michael Wonder on 06 Jan 2026
Arrowhead Pharmaceuticals announces Health Canada approval of Redemplo (plozasiran) to reduce triglycerides in adults with familial chylomicronaemia syndrome
5 January 2026 - The Health Canada approval is based on positive results from the Phase 3 PALISADE study where Redemplo significantly reduced triglycerides from baseline and lowered the numerical incidence of acute pancreatitis compared to placebo.
Arrowhead Pharmaceuticals today announced that Health Canada has issued a Notice of Compliance authorising Redemplo (plozasiran), a small interfering RNA medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronaemia syndrome for whom standard triglyceride lowering therapies have been inadequate.
